A groundbreaking experimental drug has shown potential in doubling survival time for patients with pancreatic cancer. This development is being hailed as a significant breakthrough against one of the deadliest forms of cancer.

<img alt="Man standing in field: Menta &quot;Steve&quot; Wallace poses for a portrait at his home in The Woodlands, Texas in late May." height="349" src="https://i.cbc.ca/ais/2e3806e1-27fc-4309-88d5-5f91bb5fdde5,1780333979352/full/max/0/default.jpg?im=Crop%2Crect%3D%280%2C42%2C5379%2C3025%29%3BResize%3D%28620%29" title="Menta &quot;Steve&quot; Wallace poses for a portrait at his home in The Woodlands, Texas in late May. Wallace is taking daraxonrasib, an experimental pancreatic cancer drug, as p...